Evidence map›Paper›PMID 23785463›Full record

ArticlePloS one2013

Persistence of the oral probiotic Streptococcus salivarius M18 is dose dependent and megaplasmid transfer can augment their bacteriocin production and adhesion characteristics.

Jeremy P Burton, Philip A Wescombe, Jean M Macklaim, Melissa H C Chai, Kyle Macdonald, John D F Hale, John Tagg, Gregor Reid, Gregory B Gloor, Peter A Cadieux

2 registry-linked trialsAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05375396 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Assessment of Colonization of Dairy Free Probiotic Bacterium Streptococcus Salivarius From Lozenges to the Oral Cavity

TypeinterventionalSponsorJohn HaleRan2022 to 2022Enrolled30ConditionsMicrobial ColonizationArmsStreptococcus salivarius M18 lozenges, Streptococcus salivarius M18 dairy free lozenges
NCT05480020 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Colonisation Efficacy of Streptococcus Salivarius M18 Toothpaste

TypeinterventionalSponsorJohn HaleRan2022 to 2022Enrolled30ConditionsMicrobial ColonizationArmsStreptococcus salivarius M18 toothpaste
3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Probiotics in addition to antibiotics for the treatment of acute tonsillitis: a randomized, placebo-controlled study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015
    Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Oral hygiene agents at work: effects onFrontiers in cellular and infection microbiology · 2026
    Review
  10. Effectiveness ofFrontiers in immunology · 2026
    Article
  11. Article
  12. Adjunctive use of3 Biotech · 2025
    Article
  13. Life (Basel, Switzerland) · 2024
    Review
  14. Article
  15. Article
  16. Study the effect ofFrontiers in nutrition · 2024
    Article
  17. Antimicrobial effect of probiotic bacteriocins onJournal of oral microbiology · 2024
    Article
  18. Review
  19. Study on the fermentation effect ofFrontiers in nutrition · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jeremy P BurtonCanadian Research and Development Centre for Probiotics, Lawson Health Research Institute, London, Ontario, Canada. Jeremy.burton@Lawsonresearch.com
Philip A Wescombe
Jean M Macklaim
Melissa H C Chai
Kyle Macdonald
John D F Hale
John Tagg
Gregor Reid
Gregory B Gloor
Peter A Cadieux

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacteriocin-producing probiotic Streptococcus salivarius M18 offers beneficial modulatory capabilities within the oral microbiome, apparently through potent inhibitory activity against potentially deleterious bacteria, such as Streptococcus pyogenes. The oral cavity persistence of S. salivarius M18 was investigated in 75 subjects receiving four different doses for 28 days. Sixty per cent of the subjects already had some inhibitor-producing S. salivarius in their saliva prior to probiotic intervention. Strain M18's persistence was dependent upon the dose, but not the period of administration. Culture analysis indicated that in some individuals the introduced strain had almost entirely replaced the indigenous S. salivarius, though the total numbers of the species did not increase. Selected subjects showing either high or low probiotic persistence had their salivary populations profiled using Illumina sequencing of the V6 region of the 16S rRNA gene. Analysis indicated that while certain bacterial phenotypes were markedly modulated, the overall composition of the oral microbiome was not modified by the probiotic treatment. Megaplasmids encoding bacteriocins and adhesion factors were transferred in vitro to generate a transconjugant S. salivarius exhibiting enhanced antimicrobial production and binding capabilities to HEp-2 cells. Since no widespread perturbation of the existing indigenous microbiota was associated with oral instillation and given its antimicrobial activity against potentially pathogenic streptococci, it appears that application of probiotic strain M18 offers potential low impact alternative to classical antibiotic prophylaxis. For candidate probiotic strains having relatively poor antimicrobial or adhesive properties, unique derivatives displaying improved probiotic performance may be engineered in vitro by megaplasmid transfer.

Indexed as

Bacterial AdhesionBacterial ProteinsBacteriocinsCell LineConjugation, GeneticHumansMicrobiotaMouthPlasmidsProbioticsRNA, Ribosomal, 16SSalivaSequence Analysis, DNAStreptococcusBacterial ProteinsBacteriocinsRNA, Ribosomal, 16S

Identifiers

PMID23785463
PMCPMC3681767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.